+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Acalabrutinib"

Global Hematologic Malignancies Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Thumbnail Image

Global Hematologic Malignancies Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • February 2024
  • 111 Pages
  • Global
From
Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026 - Product Thumbnail Image

Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026

  • Report
  • June 2020
  • 753 Pages
  • Global
From
Acalabrutinib - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

Acalabrutinib - Emerging Insight and Market Forecast - 2030

  • Report
  • February 2021
  • 50 Pages
  • Global
From
Acalabrutinib - Launch Insight, 2019 - Product Thumbnail Image

Acalabrutinib - Launch Insight, 2019

  • Report
  • January 2019
  • 50 Pages
  • Global
From
Advances in Cancer Signal Transduction and Therapy - Product Thumbnail Image

Advances in Cancer Signal Transduction and Therapy

  • Book
  • October 2020
From
Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1 - Product Thumbnail Image

Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1

  • Book
  • May 2023
  • 512 Pages
  • 7 Results (Page 1 of 1)
Loading Indicator

Acalabrutinib is a type of oncology drug used to treat certain types of cancer. It is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking the activity of BTK, a protein that helps certain cancer cells to grow and spread. Acalabrutinib is used to treat mantle cell lymphoma, a type of non-Hodgkin's lymphoma, and chronic lymphocytic leukemia (CLL). It is also being studied for use in other types of cancer. Acalabrutinib is available in tablet form and is taken orally. Common side effects include diarrhea, nausea, fatigue, and muscle or joint pain. More serious side effects may include an increased risk of infection, bleeding, and low blood cell counts. Acalabrutinib is marketed by several companies, including AstraZeneca, Gilead Sciences, and AbbVie. Show Less Read more